Cost-Effectiveness of Long-Term Ticagrelor in Patients With Prior Myocardial Infarction: Results From the PEGASUS-TIMI 54 Trial.

[1]  M. Gold.  Cost-effectiveness in health and medicine , 2016 .

[2]  Deepak L. Bhatt,et al.  Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease. , 2016, Journal of the American College of Cardiology.

[3]  Deepak L. Bhatt,et al.  Reduction in Ischemic Events With Ticagrelor in Diabetic Patients With Prior Myocardial Infarction in PEGASUS-TIMI 54. , 2016, Journal of the American College of Cardiology.

[4]  Marc P. Bonaca,et al.  Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54. , 2016, European heart journal.

[5]  D. Adams,et al.  Cost-Effectiveness of Transcatheter Aortic Valve Replacement With a Self-Expanding Prosthesis Versus Surgical Aortic Valve Replacement. , 2016, Journal of the American College of Cardiology.

[6]  M. Valgimigli,et al.  Impact of greater than 12-month dual antiplatelet therapy duration on mortality: Drug-specific or a class-effect? A meta-analysis. , 2015, International journal of cardiology.

[7]  Marc P. Bonaca,et al.  Efficacy and safety of ticagrelor for long-term secondary prevention of atherothrombotic events in relation to renal function: insights from the PEGASUS-TIMI 54 trial. , 2015, European heart journal.

[8]  Marc P. Bonaca,et al.  Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials. , 2015, European heart journal.

[9]  A. Jacobs,et al.  Benefits and Risks of Extended Duration Dual Antiplatelet Therapy After PCI in Patients With and Without Acute Myocardial Infarction. , 2015, Journal of the American College of Cardiology.

[10]  T. Jernberg,et al.  Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective. , 2015, European heart journal.

[11]  Marc P. Bonaca,et al.  Long-term use of ticagrelor in patients with prior myocardial infarction. , 2015, The New England journal of medicine.

[12]  G. Lip,et al.  Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials , 2015, BMJ : British Medical Journal.

[13]  K. Anstrom,et al.  Economic analysis of ticagrelor therapy from a U.S. perspective: results from the PLATO study. , 2015, Journal of the American College of Cardiology.

[14]  Braunwald,et al.  Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. , 2014, The New England journal of medicine.

[15]  Marc P. Bonaca,et al.  Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial. , 2014, American heart journal.

[16]  L. Levin,et al.  Health-related quality of life of ticagrelor versus clopidogrel in patients with acute coronary syndromes-results from the PLATO trial. , 2013, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[17]  Marc P. Bonaca,et al.  Vorapaxar in the secondary prevention of atherothrombotic events. , 2012, The New England journal of medicine.

[18]  W. O’Neill,et al.  Cost-Effectiveness of Transcatheter Aortic Valve Replacement Compared With Standard Care Among Inoperable Patients With Severe Aortic Stenosis: Results From the Placement of Aortic Transcatheter Valves (PARTNER) Trial (Cohort B) , 2012, Circulation.

[19]  F. Van de Werf,et al.  Underestimated and under-recognized: the late consequences of acute coronary syndrome (GRACE UK-Belgian Study). , 2010, European heart journal.

[20]  Deepak L. Bhatt,et al.  Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. , 2010, JAMA.

[21]  Irina Proskorovsky,et al.  Cost-Effectiveness of Prasugrel Versus Clopidogrel in Patients With Acute Coronary Syndromes and Planned Percutaneous Coronary Intervention: Results From the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in Myocardial Infarction TRI , 2010, Circulation.

[22]  Claes Held,et al.  Ticagrelor versus clopidogrel in patients with acute coronary syndromes. , 2009, The New England journal of medicine.

[23]  Deepak L. Bhatt,et al.  Cost-effectiveness of clopidogrel plus aspirin versus aspirin alone for secondary prevention of cardiovascular events: results from the CHARISMA trial. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[24]  Deepak L. Bhatt,et al.  One-Year Costs in Patients With a History of or at Risk for Atherothrombosis in the United States , 2008, Circulation. Cardiovascular quality and outcomes.

[25]  E. Antman,et al.  Prasugrel versus clopidogrel in patients with acute coronary syndromes. , 2007, The New England journal of medicine.

[26]  Deepak L. Bhatt,et al.  Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. , 2007, Journal of the American College of Cardiology.

[27]  Deepak L. Bhatt,et al.  One-year cardiovascular event rates in outpatients with atherothrombosis. , 2007, JAMA.

[28]  Patrice Cacoub,et al.  Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. , 2006, The New England journal of medicine.

[29]  S. Yusuf,et al.  Long-term cost-effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevation. , 2005, Journal of the American College of Cardiology.

[30]  Stephen Joel Coons,et al.  US Valuation of the EQ-5D Health States: Development and Testing of the D1 Valuation Model , 2005, Medical care.

[31]  A I Mushlin,et al.  The cost-effectiveness of automatic implantable cardiac defibrillators: results from MADIT. Multicenter Automatic Defibrillator Implantation Trial. , 1998, Circulation.

[32]  M. Johannesson,et al.  Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group. , 1997, The New England journal of medicine.

[33]  B. Efron.  Better Bootstrap Confidence Intervals , 1987 .

[34]  L. Shaw,et al.  ACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines. , 2014, Journal of the American College of Cardiology.

[35]  Mark Sculpher,et al.  Subgroups and Heterogeneity in Cost-Effectiveness Analysis , 2012, PharmacoEconomics.

[36]  S. Yusuf,et al.  Long-term cost-effectiveness of early and sustained clopidogrel therapy for up to 1 year in patients undergoing percutaneous coronary intervention after presenting with acute coronary syndromes without ST-segment elevation. , 2006, American heart journal.

[37]  P. R. R. Ecurrent,et al.  EFFECTS OF CLOPIDOGREL IN ADDITION TO ASPIRIN IN PATIENTS WITH ACUTE CORONARY SYNDROMES WITHOUT ST-SEGMENT ELEVATION , 2001 .

[38]  N. Arber,et al.  Platelet hyperreactivity and prognosis in survivors of myocardial infarction. , 1990, The New England journal of medicine.